Forget all your worries and refresh your mood with relaxing music and get peaceful sleep with sleep music here. Try our soothing music and experience its magic.http://www.easysleepmusic.com
EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7269351-enteromedics-fda-approval-vbloc-maestro-system-weight-loss-device/
On June 5, CVS/pharmacy kicked-off its 10th annual in-store fundraising campaign -- “Researching a Cure” -- to support the fight against amyotrophic lateral sclerosis (ALS). Funds raised through the campaign benefit the ALS Therapy Alliance (ATA), a leading organization dedicated to advancing ALS research. Through the Researching a Cure campaign, CVS/pharmacy has raised more than $23 million in its stores and online at www.cvs.com, to fund new clinical research with the aim of discovering a treatment or cure for ALS. The 2011 campaign will run through June 25.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvs/50475/
The launch of the fall television season is underway and with it, the influx of commercial interruptions. Lexus is offering an alternative to the traditional 30-minute sitcom with the debut of its fourth season of L Studio. The popular broadband channel, which has delivered such award-winning entertainment as “Web Therapy” and “Puppy Love,” is now partnering with Academy Award-winning screenwriter Diablo Cody (“Juno”) to debut her Web series “Red Band Trailer.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/52359-lexus-l-studio-diablo-cody-red-band-trailer-celebrity-interviews
Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, announces the FDA clearance of the pocket-sized PICO◊ system, a single use Negative Pressure Wound Therapy (NPWT) system. PICO is cleared for use both in a hospital and homecare setting and expands the use of NPWT from the traditional wound care population to include a wider range of patients undergoing orthopaedic surgery, plastic surgery and general surgical procedures. This FDA clearance follows the recent successful launch of PICO in Europe, Canada, and Australia.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51011-smith-nephew-pico-system-fda-approval-npwt
Philips Respironics, a unit of Royal Philips Electronics (NYSE: PHG, AEX: PHI), is introducing its latest advancement in oxygen therapy. SimplyGo is the only portable oxygen concentrator (POC) to offer continuous flow (up to 2 liters per minute) and pulse-dose delivery in a single device weighing 10 pounds or less. With this combination of capabilities, the SimplyGo POC helps homecare providers manage the therapy and lifestyle needs of nearly all oxygen users.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54713-philips-respironics-simplygo-portable-oxygen-concentrator
Approximately 80 million American men and women experience some form of hair loss. Premature balding or thinning hair can often result in a decrease of self esteem. Freedom Laser Therapy of Los Angeles is dedicated to change all that by bringing their iRestore Hair Rejuvenation System to the mass market.
This proven, safe Laser Hair Restoration Technology, otherwise known as phototherapy, is a scientific process providing stimulation to cells in your hair. The 25-year old advanced low-level laser treatment stimulates the scalp, allowing miniaturized and dormant hair follicles to rejuvenate.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54394-freedom-laser-therapy-laser-hair-treatment-regrowth-restoration
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Using a combination of 160 high-resolution tungsten leaves and dramatically faster leaf movement, Elekta’s revolutionary new Agility™* MLC promises a new level of precision and delivery speed in radiation therapy treatments for cancer patients. Elekta recently received 510(k) clearance (K121328) from the U.S. Food and Drug Administration (FDA) for Agility, enabling U.S. medical centers to provide these clinical benefits to their patients with cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55638-elekta-agility-radiation-therapy-radiotherapy-cancer-sbrt
Philips Respironics, a unit of Royal Philips Electronics (NYSE: PHG, AEX: PHI) and a pioneer in science-based sleep solutions, is simplifying the design, fitting and care of full-face masks for sleep apnea patients. With its unique modular design, the new Amara full-face mask further demonstrates Philips’ commitment to developing solutions aimed at improving care and outcomes.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57117-philips-respironics-revolutionary-full-face-mask-sleep-therapy
